Cargando…
1128. Efficacy and Safety of Nelfinavir in Asymptomatic and Mild COVID-19 Patients: A Multicenter, Randomized Controlled Trial
BACKGROUND: Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibited the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. To evaluate the efficacy and safety of nelfinavir, we conducted a randomized controlled trial. METHOD...
Autores principales: | Kohno, Shigeru, Miyazaki, Taiga, Hosogaya, Naoki, Morimoto, Shinpei, Yamamoto, Hiroshi, Iwami, Shingo, Miyazaki, Yoshitsugu, Hanaoka, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752835/ http://dx.doi.org/10.1093/ofid/ofac492.967 |
Ejemplares similares
-
Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial
por: Hosogaya, Naoki, et al.
Publicado: (2021) -
A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19
por: Miyazaki, Taiga, et al.
Publicado: (2023) -
Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study
por: Nakamura, Shigeki, et al.
Publicado: (2017) -
Radiographic Measurements on Hindfoot Alignment View in 1,128 Asymptomatic Subjects
por: Choi, Jun Young, et al.
Publicado: (2020) -
An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial
por: Koga, Tomohiro, et al.
Publicado: (2020)